Patent Expirations Through 2016 Predicted to Lower Brand Spending by $127 Billion

Dollar savings based on the conversion from brand to generic medications in the years from 2012 to 2016 will be unprecedented.

The U.S. share of global drug spending is expected to decline from 41 percent in 2006 to 31 percent by 2016, primarily due to patent expiries and slower brand growth. In the U.S. and led by Lipitor, $103 billion (44%) of 2011 brand spending will shift to generics with substantially lower prices. Major U.S. brand products, including Plavix, Seroquel, Singulair, Actos and Viagra undergo patent expiration in 2012, with the “patent cliff” continuing through 2016. Patent expirations for over 36 major brands, slower market uptake for new molecular entities, and efforts from health plans and regulators to curtail drug spending shrink brand dollars in the U.S. market through 2016.

Patent expirations up to 2016 will reduce brand spending in worldwide developed markets by $127 billion, but will be counterbalanced by generic spending, resulting in a five-year global savings of close to $106 billion. In Japan, the UK, France and Germany, many of the same or similar brands that were impacted in the U.S. will also lose patent protection. For example, in Japan, the use of generics is expected to increase as the government promotes policies to use lower-cost alternatives, and major products face generic competition. Overall, exclusivity loss in one or more developed markets will impact seven of the top 10 leading prescription drugs, including Lipitor, Plavix, Advair Diskus, Crestor, and Nexium.

Source: IMS Institute for Healthcare Informatics. The Global Use of Medicines: Outlook Through 2016. July 2012.

Protection Expiry Year US Japan UK France Germany
2012 Plavix
Seroquel
Singulair
Actos
Lexapro
Diovan
Diovan HCT®
Geodon
Viagra
Boniva
Nu Lotan
Myslee
Preminent Haigou
Seroquel
Lipitor
Amias
Seroquel
Aricept®
Singulair
Tahor
Singulair
Pariet
Ixprim
Aprovel
Seroquel
Atacand
Atacand Plus
Sortis
Aricept
2013 Oxycontin®
Aciphex
Zometa
Xeloda
Opana ER
Asacol
Diovan
Plavix
Livalo
Elplat
Viagra
Xeloda
Seretide
Coaprovel
Xeloda
Micardis
Viagra
Viani
Zometa
Atmadisc
Coaprovel
Viagra
2014 Nexium®
Cymbalta
Celebrex
Symbicort
Lunesta
Restasis
Evista
Sandostatin LAR
Actonel
Prograf
Glivec
Abilify
Abilify
Cipralex
Risperdal Consta
Seroplex
Abilify
Ebixa
Risperdal Consta LP
Axura
Risperdal Consta
Blopress Plus
2015 Abilify
Copaxone
Gleevec
Namenda
Provigil
Combivent
Zyvox
Prezista
Avodart
Zyprexa
Adoair
Alimta
Spiriva
Symbicort
Spiriva
Cymbalta
Alimta
Alimta
Spiriva
Copaxone
Protelos
Cymbalta
Spiriva
Copaxone
Alimta
Cymbalta
2016 Crestor
Benicar
Benicar HCT
Cubicin
Blopress
Baraclude
Glivec
Vfend
Glivec
Cancidas
Vfend
Glivec
Zyvoxid
Vfend

Appendix Notes:
Largest products (U.S.:>=$500Mn, Others: Top 2-5) with protection expiries in the 2012-2016 period, listed in descending order by country sales in constant US$ at Q4 2011 exchange rates. Estimates of protection expiry from information available as of March 31, 2012.
Source: IMS MIDAS, May 2012

Last updated: 2014-02-10 by Leigh Anderson, PharmD.

Hide
(web2)